Table 2 The clinical features of enrolled patients and subgroups

From: Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression

 

Control group

Experimental group

Administration

  

 Conventional treatment

√

√

 Hymecromone treatment

×

√

 Numbers

50

94

Age

 Median (range)—year

35 (21–69)

41.5 (21–77)

 ≤29, n (%)

13 (26.00%)

21 (22.34%)

 30–39, n (%)

16 (32.00%)

19 (24.47%)

 40–49, n (%)

10 (20.00%)

23 (24.47%)

 50–59, n (%)

6 (12.00%)

22 (23.40%)

 ≥60, n (%)

5 (10.00%)

5 (5.32%)

Gender

 Female (%)

14 (28.00%)

31 (32.98%)

 Male (%)

36 (72%)

63 (67.02%)

Disease severitya

 Mild, n (%)

21 (42.00%)

28 (29.79%)

 Severe, n (%)

29 (58.00%)

66 (70.21%)

Comorbidities

 None, n (%)

36 (72.00%)

76 (80.85%)

 Diabetesb, n (%)

5 (10.00%)

6 (6.38%)

 Hypertensionc, n (%)

5 (10.00%)

9 (9.57%)

 Steatohepatitisd, n (%)

3 (6.00%)

3 (3.19%)

 Asthmae, n (%)

0 (0.00%)

1 (1.06%)

 Hypohepatiaf, n (%)

0 (0.00%)

1 (1.06%)

 Hepatitisg, n (%)

2 (4.00%)

3 (3.19%)

 Blood diseasesh, n (%)

1 (2.00%)

1 (1.06%)

  1. aDisease severity was diagnosed at the patient’s admission
  2. bPatients with diabetes were treated with one or more drugs as follows: Metformin, Glimepiride, Jardiance, and Sitagliptin
  3. cPatients with hypertension were treated with one or more drugs as follows: Nifedipine, Perindopril, Amlodipine, Telmisartan, Felodipine, and Irbesartan
  4. dPatients with steatohepatitis were treated with Dangfei Liganning capsules
  5. ePatients with asthma were treated with Salmeterol
  6. fThere was no documented history for the drug treating the hypohepatia
  7. gPatients with hepatitis were treated with Tenofovir
  8. hBlood diseases included hyperuricemia, hyperlipemia, and anemia. There was no documented history for the drug treating these blood diseases
Back to article page